Drug Alerts & Adverse Event Reporting

Drug Alert


Prolia (denosumab) is an injectable RANK ligand inhibitor that is indicated for use in adults with increased fracture use due to osteoporosis, due to treatment with androgen deprivation therapy for prostate cancer, or due to treatment with adjuvant aromatase inhibitor therapy for breast cancer. It is associated with an increased risk for hypocalcemia, osteonecrosis of the jae, atypical subtrochanteric and diaphyseal femoral fractures, serious infections, and dermatologic reactions. Physicians should refer to the Risk Evaluation Mitigation Strategy(www.proliahcp.com) when prescribing this medication.

Receive Drug Alerts

The AAFP has partnered with PDR Drug Alerts(www.pdr.net) to help you receive FDA-mandated and product-related patient safety alerts as soon as they are issued.

Features of PDR Drug Alerts include:

  • Ability to appoint a family medicine team member to manage practice alerts
  • Free for U.S.-based prescribers
  • Traditional "dear doctor letter" (DDL) sent when online alert has not been reviewed within 72 hours (weekends not included)
  • Email addresses kept secure and confidential
  • Access to 12-month alert history master file
  • No advertisements
  • Information paid for by manufacturers required by the FDA to deliver safety alerts
  • Exclusive specialty-specific service fulfilling FDA guidance for electronic delivery of drug warnings

Get PDR Drug Alerts

Receive urgent FDA-mandated and product-related patient-safety alerts from PDR Drug Alerts.

Adverse Event Reporting

Using RxEvent, U.S. physicians and other health care providers can easily and effectively report adverse drug events. This service is a collaboration of medical professional insurance carriers and governmental experts.

Features of RxEvent include:

  • Easy-to-use, standardized report form with pre-populated information
  • Minimal required questions
  • Prompt acknowledgment sent upon submission of a report

RxEvent has been established for use by U.S. health care professionals for reporting adverse events on U.S.-distributed drugs only.


U.S. health care professionals may report adverse events on U.S.-distributed drugs only.